CRO expands oncology, adds functional service provider capabilities, strengthens global reach, and accelerates technology to enhance customer value ...
Sapu Bioscience announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, stre...
QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 68838...
MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative disea...
-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...
US ACT on Health Equity contributions support AstraZeneca’s long-term ambition in health equity and total more than $18 million to date ...
New AI diagnostic, Vitara Pancreas ChemoPredict, can select optimal first-line treatment for advanced pancreatic cancer patients. Valar Labs, ...
Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Ad...
Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. announced ...
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $1...
Azenta, Inc. announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge s...
A team from Knobbe Martens obtained a decisive win for medical device manufacturer Applied Medical against Medtronic, Inc. in an antitrust case involving...
MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, announced positive Phase 1 results for TML-6, it...
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significant...
© 2026 Biopharma Boardroom. All Rights Reserved.
